American Heart Month: Cardiovascular Care in Practice

Key updates include treatment thresholds, dietary recommendations, and management strategies.

Experts say SMS-based engagement tools can help pharmacists improve medication adherence and reduce hospital readmissions by addressing common patient barriers such as forgetfulness and cost.

Updated guidelines on PA call for expanded screening, treatment, and monitoring, creating opportunities for pharmacists to screen all patients with hypertension.

Cardiotoxic signals released from the kidneys may drive cardiovascular risk in patients with chronic kidney disease, opening the door to earlier detection and targeted treatment.

Patients with chronic kidney disease (CKD) send miRNA extracellular vesicles to the heart, contributing to the pathogenesis of heart failure.

The short message service (SMS) text reminders were targeted toward vulnerable patient populations and consequently reduced rates of readmission to the hospital.

Ann Marie Navar, MD, PhD, explains how enlicitide decanoate delivers LDL-C reductions comparable with injectable PCSK9 inhibitors, which could improve access to nonstatin therapy for patients not at goal.

In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease.

Ali Dehghani, DO, highlights that shingles vaccination not only prevents rash but is also associated with lower risks of major cardiovascular events, dementia, and mortality, underscoring pharmacists’ role in patient counseling and preventive care.

The vouchers are intended to speed up review times for drugs that could fill key unmet needs for Americans.

Patients with type 2 diabetes (T2D) who initiated statins experienced reductions in major cardiovascular disease (CVD) and mortality across a spectrum of predicted 10-year risk.

Intravenous laser irradiation of blood shows promise in lowering triglycerides and improving lipid profiles in patients with dyslipidemia.

There are evolving recommendations for aspirin use, including optimal drug dosages and patient selection for effective cardiovascular prevention.

High levels of C-reactive protein in the blood and lower heart rate variability were linked to cardiovascular events in patients with depression, anxiety, or both.

Lowering blood glucose levels significantly reduces heart disease risks in prediabetes, offering new hope for prevention and management strategies.

In patients with ST-segment elevation myocardial infarction, lowering low-density lipoprotein cholesterol to optimal levels prevented neoatherosclerosis, a complication following stent implantation.

The novel agent has demonstrated efficacy in symptomatic and less severe patients with obstructive hypertrophic cardiomyopathy in thorough phase 3 clinical trials.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

The FDA has approved etripamil as the first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT), offering a rapid, effective treatment that can be used outside of health care settings.

Asundexian shows promise in reducing ischemic stroke risk without increasing major bleeding, offering hope for secondary stroke prevention.

Depression and cardiometabolic disease share hormonal, inflammatory, and behavioral pathways requiring integrated pharmacist-led recognition and management.

Biykem Bozkurt, MD, PhD, FACC, highlights the need for reliable activity monitoring in heart failure care, addressing challenges of digital wearables in clinical practice.

Discover how objective activity monitoring with accelerometers transforms cardiovascular risk assessment and treatment evaluation, enhancing patient care for pharmacists.

A new wrist-worn accelerometer device effectively monitors activity levels in heart failure patients, revealing critical insights into cardiovascular health.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.